Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 13Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Advanced Pancreatic Cancer 3Esophageal Neoplasms 2Biliary Tract Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Staging IV NSCLC 1Squamous Cell Carcinoma of Lung 1Solid Tumor 1Sertoli-Leydig Cell Tumor 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Ovarian gynandroblastoma 1Obesity 1Neurotoxicity Syndromes 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Liver Neoplasms 1HER2-negative Breast Cancer 1HER2+ Breast Cancer 1

Interventions

eribulin 2tislelizumab 1camrelizumab 1anlotinib 1Vinorelbine 1Taxes 1Epirubicin 1Doxorubicin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × HER2-negative Breast Cancer × Taxes × Clear all
NCT04498793 2020-09-03

Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
55 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡